- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01982448
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response (residual cancer burden (RCB)-0/1) to singleagent cisplatin or paclitaxel.
This prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage I-III TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score >=33. Crossover to an alternative chemotherapy was offered if there was inadequate response.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University Of Alabama
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University- Simon Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Weymouth, Massachusetts, United States, 02190
- South Shore Hospital
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Cancer Center-Basking Ridge
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Cancer Center-Monmouth
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Cancer Center-Commack
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Cancer Center-West Harrison
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
Rockville Centre, New York, United States, 11570
- Memorial Sloan Kettering Cancer Center-Rockville Centre
-
Sleepy Hollow, New York, United States, 10591
- Memorial Sloan Kettering Cancer Center-Sleepy Hollow
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina- Lineberger Cancer Center
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Universtiy of Pittsburgh- Magee-Womens Hospital
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Washington
-
Kirkland, Washington, United States, 98034
- Seattle Cancer Alliance at EvergreenHealth
-
Seattle, Washington, United States, 98195
- University of Washignton
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must meet the following criteria on screening examination to be eligible to participate in the study
- Pathologic documentation of invasive breast cancer by biopsy (FNA alone is not adequate).
- AJCC clinical stage I with T1 > 1.5 cm, stage II or III invasive breast cancer.
- Participants with multicentric or bilateral disease are eligible if at least one lesion meets stage eligibility criteria for the study and no tumor is HER2-positive.
- Tumors must be HER2 negative defined as HER2 0 or 1+ by immunohistochemistry (IHC) assays and /or lack of gene amplification by FISH defined as a ratio < 2 on invasive tumor by local review.
- ER and PgR status by IHC must be known. Tumor must be ER and PR negative (≤5% staining) by local review.
- Known BRCA1/2 (BReast CAncer) status is not required for study entry. However patients known to have a germline deleterious BRCA1/2 mutation should be encouraged to consider a preoperative trial specifically designed for BRCA1/2 carriers, if available.
- Breast imaging should include imaging of the ipsilateral axilla. For subjects with a clinically positive axilla, a needle aspiration, core biopsy or SLN procedure will be performed to confirm the presence of metastatic disease in the lymph nodes.
For patients with a clinically negative axilla, baseline assessment of the axilla will be performed at the discretion of the treating investigator.
For patients with pathologically positive axillary lymph nodes prior to preoperative therapy, a level I and II lymph node dissection at the time of definitive surgery is recommended.
9. Patients with a prior history of contra-lateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer within the last 5 years.
10. Women ≥ 18 years of age. 11. ECOG performance status ≤1 (see Appendix A). 12. Laboratory Evaluation
- Absolute neutrophil count (ANC) ≥ 1,500 / mm3
- Platelet count ≥ 100,000/ mm3
- Bilirubin ≤ 1.5x upper limit of normal (ULN), for patients with Gilbert syndrome, direct bilirubin will be measured instead of total bilirubin
- ALT, AST ≤3.0 x ULN ALK Phos <2.5 x ULN
- Creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 cc/min
- Hemoglobin ≥ 9 mg/dl
- Use of an effective means of contraception is required in subjects of childbearing potential since study agents are known to be teratogenic. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
- Ability to understand and the willingness to sign a written informed consent document
- Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy and did not receive prior chemotherapy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
- Patient must be willing to undergo mandatory research biopsy and blood draw. Prior to biopsy procedures patients must be able to be off medications that could increase the risk of bleeding
Exclusion Criteria:
- Participants with axillary adenopathy only are not eligible for this study.
- Prior chemotherapy: Prior non-taxane or platinum containing chemotherapy will be allowed if the prior exposure was at least 5 years ago and the exposure is thought not to potentially interact with the primary outcome of the trial or put the patient at undue risk, and should be reviewed with study PI on a case by case basis.
- Any prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapy.
- Ipsilateral breast recurrence, unless prior treatment consisted of excision alone for DCIS or breast conserving treatment and hormonal therapy for DCIS or invasive breast cancer.
- Ongoing use of any other investigational or study agents.
- Peripheral neuropathy of any etiology > grade 1 (NCI CTCAE Version 4.0- Appendix B)
- Significant hearing loss that would prevent cisplatin administration.
- Renal dysfunction for which exposure to cisplatin would be unsafe or require cisplatin dose modification (i.e., Cre > 1.5 mg/dl or GFR < 60 cc/min).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: Cisplatin
Cisplatin given by IV infusion at a dose of 75 mg/m2 every 3 weeks (1 cycle) for 4 cycles as preoperative chemotherapy.
Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to crossover to an alternative provider-selected preoperative chemotherapy regimen.
Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
|
Other Names:
|
Experimental: Arm B: Paclitaxel
Paclitaxel given by IV infusion at a dose of 80 mg/m2 weekly for 12 weeks (4 cycles) as neoadjuvant chemotherapy.
Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to 'crossover' to an alternative provider-selected preoperative chemotherapy regimen.
Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Pathologic Response by HR-deficiency (HRD) Status
Time Frame: Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al.
JCO 2007).
Responders are defined as RCB 0/1 and non-responders as RCB 2/3.
Participants who crossed over due inadequate clinical response after 12 weeks were counted as non-responders.
HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair.
The positive threshold for HRD was a score >/= 33.
|
Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number With Pathologic Complete Response (pCR) by HR-deficiency (HRD) Status
Time Frame: Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al.
JCO 2007).
pCR is defined as RCB-0.
HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair.
The positive threshold for HRD was a score >/= 33.
|
Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Number of Pathologic Response
Time Frame: Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al.
JCO 2007).
Responders are defined as RCB 0/1 and non-responders as RCB 2/3.
Participants who crossed over due inadequate clinical response after 12 weeks were counted as non-responders.
HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair.
The positive threshold for HRD was a score >/= 33.
|
Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Number With Pathologic Response
Time Frame: Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al.
JCO 2007).
Responders are defined as RCB 0/1 and non-responders as RCB 2/3.
Participants who crossed over due inadequate clinical response after 12 weeks were counted as non-responders.
HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair.
The positive threshold for HRD was a score >/= 33.
|
Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Positive Predictive Value (PPV) of HRD Score
Time Frame: Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Pathologic response was assessed using the MD Anderson residual cancer burden (RCB) method (Symmans et al. JCO 2007). Responders are defined as RCB 0/1 and non-responders as RCB 2/3. Participants who crossed over due inadequate clinical response after 12 weeks were counted as non-responders. HRD status was determined with baseline diagnostic tissue using the HRD assay (Myriad Genetics, Inc.; required minimum 100 mm2 of tumor tissue) which detects impaired double-strand DNA break repair. The positive threshold for HRD was a score >/= 33. PPV was calculated as the probability of pathological response among the HRD positive group. |
Evaluated after definitive breast surgery, up to 4-5 months from enrollment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Erica Mayer, MD, Dana-Farber Cancer Institute
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-383
- TBCRC030 (Other Identifier: Translational Breast Cancer Research Consortium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple Negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Melinda TelliPfizer; BioMarin PharmaceuticalCompletedAdvanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast CancerUnited States
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
UNICANCERSOLTI Breast Cancer Research Group; Vall d'Hebron Institute of Oncology; MSD...Not yet recruitingTriple-negative Breast Cancer
-
Shanghai Jiao Tong University School of MedicineCSPC Ouyi Pharmaceutical Co., Ltd.; Innovent Biologics, Inc.Not yet recruiting
Clinical Trials on Cisplatin
-
West China Second University HospitalRecruitingNeoadjuvant Chemotherapy | Epithelial Carcinoma, OvarianChina
-
Insmed IncorporatedCompletedOsteosarcoma MetastaticUnited States
-
Privo TechnologiesNational Cancer Institute (NCI)CompletedOral Squamous Cell CarcinomaUnited States
-
Samsung Medical CenterUnknownNasophayngeal Carcinoma Between Stage II and IVbKorea, Republic of
-
Cedars-Sinai Medical CenterRecruitingHPV Positive Oropharyngeal Squamous Cell CarcinomaUnited States
-
Korea Cancer Center HospitalCompletedCervical CancersKorea, Republic of
-
Taiho Oncology, Inc.Quintiles, Inc.Completed
-
Lawson Health Research InstituteRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaCanada
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal CarcinomaChina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaboratorsActive, not recruitingNasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck NeoplasmChina